Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
Nature Reviews. Cancer|February 25, 2017
Liquid biopsies come of age: towards implementation of circulating tumour DNAJonathan C M Wan, Charles Massie, Javier Garcia-Corbacho, et al.
Frontiers in Genetics|June 23, 2023
Population genomic analysis reveals geographic structure and climatic diversification for <i>Macrophomina phaseolina</i> isolated from soybean and dry bean across the United States, Puerto Rico, and ColombiaViviana Ortiz, Hao-Xun Chang, Hyunkyu Sang, et al.
Genome Medicine|January 6, 2019
Next Generation-Targeted Amplicon Sequencing (NG-TAS): an optimised protocol and computational pipeline for cost-effective profiling of circulating tumour DNAMeiling Gao, Maurizio Callari, Emma Beddowes, et al.
Cancer Chemotherapy and Pharmacology|November 1, 2016
A phase I pharmacokinetic and safety study of cabazitaxel in adult cancer patients with normal and impaired renal functionAnalía Azaro, Jordi Rodón, Jean-Pascal Machiels, et al.
Experimental Biology and Medicine (Maywood, N.J.)|March 11, 2024
A phase 1 trial of human telomerase reverse transcriptase (hTERT) vaccination combined with therapeutic strategies to control immune-suppressor mechanismsNahid Zareian, Oleg Eremin, Hardev Pandha, et al.
Cell Reports Methods|May 27, 2026
Real-time cell viability monitoring for high-throughput drug screening using tumor xenograft-derived cellsElham Esmaeilishirazifard, Daniel Guerrero-Romero, Allan J W Lui, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 7, 2013
A phase I study of quisinostat (JNJ-26481585), an oral hydroxamate histone deacetylase inhibitor with evidence of target modulation and antitumor activity, in patients with advanced solid tumorsBalaji Venugopal, Richard Baird, Rebecca S Kristeleit, et al.
IEEE Transactions on Bio-Medical Engineering|February 6, 2013
Grand challenges in interfacing engineering with life sciences and medicineBin He, Richard Baird, Robert Butera, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 6, 2014
First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumorsDebashis Sarker, Joo Ern Ang, Richard Baird, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 21, 2014
Interrogating two schedules of the AKT inhibitor MK-2206 in patients with advanced solid tumors incorporating novel pharmacodynamic and functional imaging biomarkersTimothy A Yap, Li Yan, Amita Patnaik, et al.
Pageof 3